Immunovant, Inc. (IMVT)

NASDAQ: IMVT · IEX Real-Time Price · USD
37.50
+0.37 (1.00%)
At close: Feb 20, 2024, 4:00 PM
38.00
+0.50 (1.33%)
After-hours: Feb 20, 2024, 7:45 PM EST
1.00%
Market Cap 5.45B
Revenue (ttm) n/a
Net Income (ttm) -243.45M
Shares Out 145.29M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,444,958
Open 38.14
Previous Close 37.13
Day's Range 37.44 - 39.20
52-Week Range 14.05 - 45.58
Beta 0.74
Analysts Strong Buy
Price Target 44.00 (+17.33%)
Earnings Date Feb 12, 2024

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences L... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Peter Salzmann M.B.A., M.D.
Employees 164
Stock Exchange NASDAQ
Ticker Symbol IMVT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for IMVT stock is "Strong Buy." The 12-month stock price forecast is $44.0, which is an increase of 17.33% from the latest price.

Price Target
$44.0
(17.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

8 days ago - GlobeNewsWire

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

6 weeks ago - GlobeNewsWire

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

2 months ago - GlobeNewsWire

Best Small-Cap Stocks to Buy for 2024 and Beyond

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

2 months ago - Kiplinger

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

3 months ago - GlobeNewsWire

Immunovant to Present at Upcoming Investor Conferences

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

3 months ago - GlobeNewsWire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

3 months ago - GlobeNewsWire

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...

5 months ago - GlobeNewsWire

Immunovant Announces Pricing of $450 Million Common Stock Financing

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

5 months ago - GlobeNewsWire

Immunovant Announces Proposed Offering of $300 Million of Common Stock

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

5 months ago - GlobeNewsWire

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.

5 months ago - Investopedia

Immunovant shares surge after antibody treatment succeeds in early-stage study

Shares of Immunovant surged over 60% in premarket trading on Tuesday, after the drug developer said its antibody treatment succeeded in an early-stage trial.

5 months ago - Reuters

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

5 months ago - GlobeNewsWire

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Sept. 20, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty clai...

5 months ago - PRNewsWire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...

6 months ago - GlobeNewsWire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported c...

9 months ago - GlobeNewsWire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...

1 year ago - GlobeNewsWire

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...

1 year ago - GlobeNewsWire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...

1 year ago - GlobeNewsWire

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...

1 year ago - GlobeNewsWire

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today ...

1 year ago - GlobeNewsWire

Immunovant to Present at Roivant Investor Day on September 28th

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...

1 year ago - GlobeNewsWire

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...

1 year ago - GlobeNewsWire

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann...

1 year ago - GlobeNewsWire